

HR 5127

Curb Opioid Misuse By Advancing Technology Act of 2016

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 29, 2016

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 6, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/5127>

Sponsor

Name: Rep. Griffith, H. Morgan [R-VA-9]

Party: Republican • **State:** VA • **Chamber:** House

Cosponsors (10 total)

| Cosponsor | Party / State | Role | Date Joined |
|---------------------------------------|---------------|------|--------------|
| Rep. Bilirakis, Gus M. [R-FL-12] | R · FL | | Apr 29, 2016 |
| Rep. Connolly, Gerald E. [D-VA-11] | D · VA | | Apr 29, 2016 |
| Rep. Collins, Chris [R-NY-27] | R · NY | | Jun 15, 2016 |
| Rep. Boyle, Brendan F. [D-PA-13] | D · PA | | Jun 28, 2016 |
| Rep. Fitzpatrick, Michael G. [R-PA-8] | R · PA | | Jul 7, 2016 |
| Rep. Dold, Robert J. [R-IL-10] | R · IL | | Sep 8, 2016 |
| Rep. Veasey, Marc A. [D-TX-33] | D · TX | | Sep 8, 2016 |
| Rep. Stewart, Chris [R-UT-2] | R · UT | | Sep 19, 2016 |
| Rep. Blackburn, Marsha [R-TN-7] | R · TN | | Nov 14, 2016 |
| Rep. Wilson, Frederica S. [D-FL-24] | D · FL | | Nov 14, 2016 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------------------|---------|-------------|-------------|
| Energy and Commerce Committee | House | Referred to | May 6, 2016 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Curb Opioid Misuse By Advancing Technology Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to extend the marketing exclusivity period for certain brand name drugs that the Food and Drug Administration approves: (1) on the basis of new clinical abuse potential studies, and (2) with labeling that characterizes the drug's abuse-deterrent properties. This extension does not apply to the marketing exclusivity period for new chemical entities.

The bill also extends the marketing exclusivity period for generics of these drugs.

Actions Timeline

- **May 6, 2016:** Referred to the Subcommittee on Health.
- **Apr 29, 2016:** Introduced in House
- **Apr 29, 2016:** Referred to the House Committee on Energy and Commerce.